Production (Stage)
Minerva Neurosciences, Inc.
NERV
$1.84
$0.052.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -88.19% | 13,505.31% | |||
| Gross Profit | 88.19% | -13,505.31% | |||
| SG&A Expenses | 0.04% | 2.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.69% | 3.56% | |||
| Operating Income | 13.69% | -3.56% | |||
| Income Before Tax | 12.15% | -118.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.15% | -118.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.15% | -118.98% | |||
| EBIT | 13.69% | -3.56% | |||
| EBITDA | 13.70% | -3.56% | |||
| EPS Basic | 12.15% | -118.98% | |||
| Normalized Basic EPS | 12.16% | -118.98% | |||
| EPS Diluted | 12.15% | -119.00% | |||
| Normalized Diluted EPS | 12.16% | -118.98% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||